BMJ

1. MURPHY F
   China adds HPV shot as first new immunisation programme vaccine in 17 years.
   BMJ. 2025;390:r1985.
   

   >> Share

   
   
2. TANNE JH
   US vaccine committee changes MMR and hepatitis vaccine schedules amid criticism.
   BMJ. 2025;390:r1992.
   

   >> Share

   
   
3. SCHALTZ-BUCHHOLZER F, Bjerregaard-Andersen M
   Universal BCG vaccine at birth.
   BMJ. 2025;390:r1982.
   

   >> Share

   
   
4. ADHISIVAM B, Kamalarathnam C, Bhat BV, Jayaraman K, et al
   Effect of BCG Danish and oral polio vaccine on neonatal mortality in newborn babies weighing less than 2000 g in India: multicentre open label randomised controlled trial (BLOW2).
   BMJ. 2025;390:e084745.
   

   >> Share

   
   
5. YANG YT
   Reimagining vaccine confidence in the digital age.
   BMJ. 2025;390:r1955.
   

   >> Share

   
   

   
   Clin Infect Dis

6. GOSWAMI J, Cardona JF, Caso J, Hsu DC, et al
   Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged >/=50 Years.
   Clin Infect Dis. 2025 Sep 23:ciaf515. doi: 10.1093.
   

   >> Share

   
   
7. COLOMBO RE, Richard SA, Schmidt K, Schofield C, et al
   Randomized pragmatic trial of the comparative effectiveness of chicken egg-based inactivated, mammalian cell-culture-based inactivated, and recombinant protein quadrivalent seasonal influenza vaccines in United States Military Health System beneficiar
   Clin Infect Dis. 2025 Sep 18:ciaf503. doi: 10.1093.
   

   >> Share

   
   
8. SIZA C, Plucinski M, Lessa FC, Campelo E, et al
   Antibody Response in Healthcare Workers During the Severe Acute Respiratory Syndrome Coronavirus 2 Gamma Variant Outbreak in Manaus, Brazil.
   Clin Infect Dis. 2025 Jul 16:ciaf318. doi: 10.1093.
   

   >> Share

   
   

   
   J Immunol

9. MATHEWS J, Van Itallie E, Li Y, Wiehe K, et al
   Computing the inducibility of broadly neutralizing antibodies under a context-dependent model of affinity maturation: applications to sequential vaccine design.
   J Immunol. 2025 Sep 13:vkaf234. doi: 10.1093.
   

   >> Share

   
   

   
   J Infect Dis

10. QUACH HQ, Goergen KM, Grill DE, Ovsyannikova IG, et al
    IL-8 as a Causal Link Between Aging and Impaired Influenza Antibody Responses in Older Adults.
    J Infect Dis. 2025 Mar 17:jiaf148. doi: 10.1093.
    

    >> Share

    
    
11. WANG C, Yuan HY, Lau EHY, Cowling BJ, et al
    Impact of Population Immunity and Public Health Measures on the Transmission of Omicron Subvariants BA.2 and BA.5 in Hong Kong.
    J Infect Dis. 2025;232:e476-e485.
    

    >> Share

    
    
12. COPELAND NK, Otieno L, Otieno JD, Otieno S, et al
    Efficacy of RTS,S/AS01E only seen in baseline parasitemic and not baseline aparasitemic Plasmodium falciparum-exposed, drug-treated Kenyan adults.
    J Infect Dis. 2025 May 29:jiaf274. doi: 10.1093.
    

    >> Share

    
    
13. MATTHIAS KA, Connolly KL, Jerse AE, Kumova OK, et al
    Evaluation of Immunization Route in Induction of Vaccine-Mediated Anti-Gonococcal Immune Responses in a Murine Model of Ascending Infection.
    J Infect Dis. 2025 Sep 16:jiaf445. doi: 10.1093.
    

    >> Share

    
    
14. CARONE M, Wolock CJ, Olivas-Martinez A, Rotnitzky A, et al
    Immune Correlates and Vaccine Immunobridging: Statistical Innovations, Challenges, and Opportunities.
    J Infect Dis. 2025 Sep 16:jiaf451. doi: 10.1093.
    

    >> Share

    
    

    
    J Virol

15. ZHOU J, Cai S, Huang H, Yang F, et al
    LPS/TLR4-activated M1-polarized macrophage-derived exosomes enhance IBV vaccine efficacy in chickens.
    J Virol. 2025 Sep 23:e0115625. doi: 10.1128/jvi.01156.
    

    >> Share

    
    
16. PENG G, Zhao X, Zou X, Zhang H, et al
    An attenuated African swine fever virus with deletions of the CD2v and A137R genes offers complete protection against homologous challenge in pigs.
    J Virol. 2025;99:e0026225.
    

    >> Share

    
    
17. QU Y, Li J, Deng H, Wang Y, et al
    Viroporins: emerging viral infection mechanisms and therapeutic targets.
    J Virol. 2025;99:e0103825.
    

    >> Share

    
    
18. CHATURBHUJ DN, Sliepen K, Cupo A, Steinberg B, et al
    A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers.
    J Virol. 2025 Aug 27:e0091325. doi: 10.1128/jvi.00913.
    

    >> Share

    
    
19. DZIMIANSKI JV, Nagashima KA, Cruz JM, Sautto GA, et al
    Assessing the structural boundaries of broadly reactive antibody interactions with diverse H3 influenza hemagglutinin proteins.
    J Virol. 2025 Aug 14:e0045325. doi: 10.1128/jvi.00453.
    

    >> Share

    
    
20. SOWNTHIRARAJAN B, Mason M, Loganathan G, Manivasagam S, et al
    A versatile H5N1-VSV platform for safe influenza virus research applications.
    J Virol. 2025 Aug 8:e0097525. doi: 10.1128/jvi.00975.
    

    >> Share

    
    
21. MBOKO WP, Wang Y, Cao W, Sayedahmed EE, et al
    Trained ILCs confer adaptive immunity-independent protection against influenza.
    J Virol. 2025 Aug 4:e0053225. doi: 10.1128/jvi.00532.
    

    >> Share

    
    

    
    JAMA

22. ABBASI J
    GLP-1 Drugs in Heart Failure, beta-Blockers After MI, the Shingles Vaccine, and More From ESC 2025.
    JAMA. 2025 Sep 19. doi: 10.1001/jama.2025.15515.
    

    >> Share

    
    

    
    Lancet

23. KUEHN R, Rahden P, Hussain HS, Karkey A, et al
    Enteric (typhoid and paratyphoid) fever.
    Lancet. 2025;406:1283-1294.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

24. KASAI S, Nagata M, Toyama Y, Inage E, et al
    Emerging Invasive Haemophilus influenzae Type C Infection in a Hib-vaccinated Child: Implications for Surveillance.
    Pediatr Infect Dis J. 2025 Sep 18. doi: 10.1097/INF.0000000000005011.
    

    >> Share

    
    

    
    PLoS Comput Biol

25. MBURU C, Ojal J, Selim R, Ombati R, et al
    Modelling the relative contribution of infection, routine vaccination and supplementary immunisation activities to measles seroconversion in Kenyan Children.
    PLoS Comput Biol. 2025;21:e1013531.
    

    >> Share

    
    

    
    PLoS One

26. POLISHCHUK V, Kostinov capital EM, Cyrillic, Ryzhov capital A, Cyrillic, Dagil Y, et al
    Immunogenicity of one dose and two doses of adjuvanted influenza vaccine in lung transplant candidates.
    PLoS One. 2025;20:e0332346.
    

    >> Share

    
    
27. PAYNE LA, Edelman A, Darney BG, Benhar E, et al
    Brief report: Older adolescents and young adults may be at higher risk for changes to menstrual cycle length with COVID-19 vaccination.
    PLoS One. 2025;20:e0331346.
    

    >> Share

    
    
28. BASHORUN AO, Kotei L, Jallow AF, Jawla O, et al
    Human papillomavirus, sexually transmitted infections, and antimicrobial resistance in West Africa: Estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions: The PHASE survey protocol.
    PLoS One. 2025;20:e0332842.
    

    >> Share

    
    
29. WANG Y, Gao YD, Jiang CH, Xi Y, et al
    Characterisation of a novel chicken-derived H3N3 avian influenza virus detected in China in 2023: Pathogenicity and immunogenicity.
    PLoS One. 2025;20:e0332213.
    

    >> Share

    
    

    
    Science

30. ROBERTS L
    A shot at survival.
    Science. 2025;389:1175-1179.
    

    >> Share

    
    

    
    Vaccine

31. SARTORI AL, Buffarini R, Bertoldi AD, da Silveira MF, et al
    Association between maternal influenza vaccination and childhood vaccination among participants of the 2015 Pelotas (Brazil) birth cohort.
    Vaccine. 2025;64:127761.
    

    >> Share

    
    
32. PALACHE B, Fyyaz H, Thomson D, Taylor B, et al
    The IFPMA IVS seasonal influenza vaccine dose distribution survey 2022-2023: evidence of the need for committed national investment in and uptake of seasonal influenza vaccination.
    Vaccine. 2025;64:127747.
    

    >> Share

    
    
33. HUI S, He R, Li H, Li Y, et al
    Revealing dynamic transcriptomic and immune cell signatures underlying heterogeneous responses to influenza vaccination.
    Vaccine. 2025;64:127777.
    

    >> Share

    
    
34. SAIYED S, Dong E, Gardner LM
    The relationship between state vaccination exemption policies and MMR vaccination trends in the U.S.
    Vaccine. 2025;64:127773.
    

    >> Share

    
    
35. KAHUSU CM, Peckeu-Abboud L, Goovaerts O, Matungulu E, et al
    Corrigendum to "Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC" [Vaccine 62 (2025) 127537].
    Vaccine. 2025;64:127719.
    

    >> Share

    
    
36. BIZUAYEHU HY, Kebede Y, Deressa M, Solomon E, et al
    Pneumococcal carriage prevalence, serotype distribution, and vaccine coverage in Ethiopia 12 years after pneumococcal vaccine introduction.
    Vaccine. 2025;64:127762.
    

    >> Share

    
    
37. CUYPERS L, Dambre C, Desmet S
    Exceptional high number of IPD cases in winter season 2024-2025 in Belgium in concomitance with rise in vaccine serotypes.
    Vaccine. 2025;64:127763.
    

    >> Share

    
    
38. HODGSON A, Haidara FC, Sow SO, Ansah PO, et al
    Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.
    Vaccine. 2025;64:127698.
    

    >> Share

    
    
39. SCHERM MJ, Holzl R, Gonzalez-Dominguez I, Hjorth R, et al
    Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines.
    Vaccine. 2025;64:127671.
    

    >> Share

    
    
40. SCHIAVONE A, Edwards JC, Vigneswaran E, De Brito RCF, et al
    Evaluation of a strategy to enhance the efficacy and ease of application of porcine reproductive and respiratory syndrome virus vaccines.
    Vaccine. 2025;64:127757.
    

    >> Share

    
    
41. QIAN Y, Phillips M, Eiden AL, Carias C, et al
    Family spillover effects in cost-effectiveness analyses of vaccines.
    Vaccine. 2025;64:127755.
    

    >> Share

    
    
42. HUMPHREYS J, Blake A, Nicolay N, Braeye T, et al
    Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.
    Vaccine. 2025;64:127752.
    

    >> Share

    
    
43. WROBEL-PAWELCZYK I, Golebiewska A, Ronkiewicz P, Kiedrowska M, et al
    Changes in the Streptococcus pneumoniae population responsible for invasive disease of young children after the implementation of conjugated vaccines in the National Immunization Program in Poland.
    Vaccine. 2025;64:127759.
    

    >> Share

    
    
44. ALMEIDA GG, Pinto JA, Pinto PM, da Silva LB, et al
    Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19.
    Vaccine. 2025;64:127756.
    

    >> Share

    
    
45. ESPARZA J, Damaso CR
    The 1904 Rio De Janeiro vaccine revolt: Resistance to compulsory smallpox vaccination.
    Vaccine. 2025;64:127774.
    

    >> Share

    
    

    
    Virology

46. ELHAZAZ FERNANDEZ A, Abidi S, Mahl K, Scheffler D, et al
    A chiropteran factor of innate immunity can be recruited for rapid rescue and amplification of recombinant modified vaccinia Ankara (MVA).
    Virology. 2025;612:110698.
    

    >> Share

    
    

    
    Virus Res

47. VOKO Z, Turi G, Oroszi B, Belicza E, et al
    Association between COVID-19 vaccination and progression to severe outcomes in hospitalized COVID-19 patients in Hungary during the pre-Omicron era of the COVID-19 pandemic.
    Virus Res. 2025;361:199633.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share